So now me thinks that right now there are two schools of...

So now me thinks that right now there are two schools of thought:

(1) This "growth stock" isn't demonstrating continuation of straight-line trajectory on the top line given a lack of H2 guidance (another lesson learnt FIG management when you're now playing in the big league as a listed company) plus point-in-time escrow overhang, therefore best to move money elsewhere into other growth opportunities. Taking market share in a flat industry like insurance isn't exactly a sexy proposition.

(2) Deep value emerging with trial commission cash pile growing at $20m every year based on sales already made and assuming current level would be maintained which makes it increasing attractive in terms of NTA in the long haul, couple with a low 7x earnings multiple comparing to peers (e.g. SDF, AUB).

Judging purely by share price today it seems that most players fall into camp (1) which given the recent events have put a big dent into credibility/confidence of management.